<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04166448</url>
  </required_header>
  <id_info>
    <org_study_id>APHP190335</org_study_id>
    <nct_id>NCT04166448</nct_id>
  </id_info>
  <brief_title>LUMIERE on the PLACENTA</brief_title>
  <acronym>FETUS</acronym>
  <official_title>LUMIERE on the PLACENTA : A Study on the Added Value of MRI</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>LUMIERE Fondation ( fondation-lumiere.org) under the aegis of Fondation de France</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Paris 5 - Rene Descartes</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The frequency of IUGR is between 3 and 10% of births. The etiologies and mechanisms of IUGR&#xD;
      are multiple. The placental insufficiency, that is the defect of perfusion, is, however, the&#xD;
      principal mechanism, far in front of other maternal or fetal causes. This placental&#xD;
      insufficiency is also now recognized as an essential risk factor for cardiovascular and&#xD;
      metabolic diseases, such as diabetes, in adulthood. The interest in understanding in utero&#xD;
      development is thus further increased by the short-, medium- and long-term consequences of&#xD;
      placental dysfunction. However, there are few ways to evaluate uteroplacental vascularization&#xD;
      in vivo. MRI is an imaging technique used routinely in the exploration of the fetus in&#xD;
      addition to ultrasound. Its safety on the fetus and the mother is largely demonstrated at&#xD;
      1.5T. There are also MRI sequences used daily in the clinic to evaluate perfusion and organ&#xD;
      structure in children and adults (brain, kidney, heart, etc.). Their application for&#xD;
      evaluation of perfusion and placental structure, although still confined to research, is very&#xD;
      promising. The investigator's team has extensive experience, in animals or in children, in&#xD;
      the use of these sequences that could be used to evaluate placental function in vivo. The ASL&#xD;
      (Arterial Spin Labeling) in particular is the most encouraging functional imaging technique&#xD;
      because it allows today to measure an organ blood flow quantitatively and without injection&#xD;
      of contrast medium.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The inclusion will take place at the earliest at 20 weeks after the completion of the&#xD;
      standard morphological ultrasound of the 2nd trimester (carried out at 20-24SA) and at the&#xD;
      latest at 35 SA, within the framework of one of the 2 clinical subgroups of patients&#xD;
      considered (high risk and low risk).&#xD;
&#xD;
      The objectives of this study will be achieved by the prospective setting up of a LUMIERE&#xD;
      cohort on PLACENTA.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Never start&#xD;
  </why_stopped>
  <start_date type="Anticipated">December 2019</start_date>
  <completion_date type="Anticipated">November 2023</completion_date>
  <primary_completion_date type="Anticipated">June 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in placental blood flow as seen in vascular IUGR</measure>
    <time_frame>From inclusion to end of neonatal period (max 25 weeks)</time_frame>
    <description>25% reduction in overall placental perfusion measured ASL with IUGR (defined as &lt;3th perc birth weight) versus controls (birth weight&gt; 10th perc)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Placental response to maternal oxygenation (BOLD)</measure>
    <time_frame>From inclusion to end of neonatal period (max 25 weeks)</time_frame>
    <description>BOLD effect</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>structural changes of the placenta</measure>
    <time_frame>From inclusion to end of neonatal period (max 25 weeks)</time_frame>
    <description>Diffusion coefficient (ADC)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>structural changes of the placenta</measure>
    <time_frame>From inclusion to end of neonatal period (max 25 weeks)</time_frame>
    <description>T2 * mapping</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measurement of placental volume</measure>
    <time_frame>From inclusion to end of neonatal period (max 25 weeks)</time_frame>
    <description>Placental segmentation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measurement of IUGR by fetal segmentation (MRI),</measure>
    <time_frame>From inclusion to end of neonatal period (max 25 weeks)</time_frame>
    <description>Fetal volume</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>evaluation of brain resonance</measure>
    <time_frame>From inclusion to end of neonatal period (max 25 weeks)</time_frame>
    <description>BOLD effect, - ADC coefficient and IVIM parameters by variation of T2 * relaxation time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>evaluation of kidney resonance</measure>
    <time_frame>From inclusion to end of neonatal period (max 25 weeks)</time_frame>
    <description>BOLD effect, - ADC coefficient and IVIM parameters by variation of T2 * relaxation time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>evaluation of liver resonance</measure>
    <time_frame>From inclusion to end of neonatal period (max 25 weeks)</time_frame>
    <description>BOLD effect, - ADC coefficient and IVIM parameters by variation of T2 * relaxation time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reproducibility of the examination analysis</measure>
    <time_frame>After study completion, an average of one year</time_frame>
    <description>Correlations between microcirculatory parameters in utero, fetal weight at MRI and birth weight</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Uterine arteries</measure>
    <time_frame>From inclusion to end of neonatal period (max 25 weeks)</time_frame>
    <description>Measurement of blood flow in the uterine arteries by MRI 4D FLOW (in development) and Doppler (US) (feasibility study)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acceptability of the examination for the patient: questionnaire</measure>
    <time_frame>at IRM examination</time_frame>
    <description>Will be assessed by a questionnaire given to pregnant women after the MRI,</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acceptability of the examination for the patient: Likert scale</measure>
    <time_frame>at IRM examination</time_frame>
    <description>will be assessed once by a Likert scale: 4 points Likert (poor, average, good, very good)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Specific Absorption Rate for each type of sequence</measure>
    <time_frame>From inclusion to end of neonatal period (max 25 weeks)</time_frame>
    <description>SAR measurement (Specific Absorption Rate)</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">0</enrollment>
  <condition>Pregnancy</condition>
  <arm_group>
    <arm_group_label>Group 1: High risk IUGR patients</arm_group_label>
    <description>EPF&lt;10th perc or PA&lt;10th perc and Doppler ombilical IP&gt; 95th percentile, EPF or PA&lt;3th perc (reference curves from Collège Français d'Echographie Fœtale, between 20 et 34 GW),</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2: Low risk IUGR patients</arm_group_label>
    <description>EPF et PA&gt;20th perc (reference curves from Collège Français d'Echographie Fœtale, between 20 et 34 GW)</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Fetal MRI</intervention_name>
    <description>The MRI examination added by this research, without injection or sedation, induces no risk for the mother as for the fetus(es)</description>
    <arm_group_label>Group 1: High risk IUGR patients</arm_group_label>
    <arm_group_label>Group 2: Low risk IUGR patients</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Pregnant patients with low and high risk of placental IUGR followed in the Fetal Medicine&#xD;
        Department of the Necker-Enfants Malades hospital.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Singleton pregnancy without fetal malformation seen on ultrasound. Group 1: High risk&#xD;
             IUGR patients&#xD;
&#xD;
               -  EPF&lt;10th perc or PA&lt;10th perc and Doppler ombilical IP&gt; 95th percentile,&#xD;
&#xD;
               -  EPF or PA&lt;3th perc reference curves from Collège Français d'Echographie Fœtale,&#xD;
                  between 20 et 34 GW,&#xD;
&#xD;
        Group 2: Low risk IUGR patients&#xD;
&#xD;
        • EPF et PA&gt;20th perc reference curves from Collège Français d'Echographie Fœtale, between&#xD;
        20 et 34 GW&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  - Contraindication to MRI&#xD;
&#xD;
          -  Impossible subsequent follow up&#xD;
&#xD;
          -  Maternal status contraindicates continuation of pregnancy&#xD;
&#xD;
          -  Participation in another search&#xD;
&#xD;
          -  &quot;Protected&quot; patient&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Laurent Salomon, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Principal Investigator</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Necker - Enfants Malades Hospital</name>
      <address>
        <city>Paris</city>
        <zip>75015</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>September 17, 2019</study_first_submitted>
  <study_first_submitted_qc>November 15, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 18, 2019</study_first_posted>
  <last_update_submitted>April 2, 2021</last_update_submitted>
  <last_update_submitted_qc>April 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

